Skip to content
Search

Latest Stories

Boots to offer £42k FTE base salary to newly-qualified pharmacists

Boots UK will offer a staring salary of £42,000 per annum to newly qualified pharmacists joining the pharmacy chain.

The company also revealed that "in addition, any existing pharmacists in the bargaining unit currently receiving less than £43k.”


The newly announced hike in the salary -- following an agreement reached between the multiple and and the Pharmacist Defence Association -- will be effective from 1 August 2022.

“This enhanced offer for Newly Qualified Pharmacists and further investment in those in the early stages of their careers at Boots is a key part of our commitments to pharmacists,” the company said.

Boots and PDA Union also announced in a joint statement that they will conduct a further formal review of all pharmacists’ pay in accordance with the collective agreement, effective from 1 November 2022.

“Those receiving this adjustment to £43k will remain part of the November 2022 pay review. Details of the November 2022 pay review will be shared in due course once this year’s pay negotiations have taken place.”

Newly-qualified Boots pharmacists' salary in past 10 years

“When the PDA Union explained to pharmacists the potential benefits of union recognition at Boots before the ballots, a significant issue identified was that NQ pharmacists starting salaries had been suppressed for many years. In the entire 10 years before union recognition, NQ starting salaries had increased by just 3 per cent (2007: £33,000 to 2018: £34,000),” said PDA.

"For the last 10 years, salaries for newly-qualified Boots pharmacists have remained almost static."

In 2007, Boots newly qualified pharmacist were offered £33,000; equivalent salary in 2017, taking into account inflation: Circa £43,527 and actual Boots newly qualified pharmacist salary 2017/18: £34,000.

“In addition, hundreds of Boots pharmacists have been disadvantaged by market-based pay which was introduced in 2014. Pharmacists’ salaries are based on undisclosed “market data” from an unspecified source,” said PDA.

“We think pharmacists should be told exactly how their salaries are being determined, and have the opportunity to negotiate better ones.”

“However, in the four years since pharmacists secured the rights to collective bargaining, these starting rates have increased by 23.5% (2018: £34,000 to 2022: £42,000). Union negotiators have also agreed with Boots that any increase to NQ pharmacist salaries cannot place NQ pharmacists on higher salaries than established colleagues, something that was not publicly guaranteed when the company decided pay rates by itself.”

While the PDA Union believes that the NQ pharmacist rates increase will significantly increase income for some lower-paid pharmacists in the bargaining unit, others will see no increase as a result of this.

The PDA Union, therefore, recognises that these increases do have an impact on differentials, closing the pay gap between brand-new pharmacists and their more experienced colleagues.

Those who have not benefitted significantly or at all under this proposal in the forthcoming pay review will be on the Union's priority.

The Union will also seek to ensure members at Boots are actively encouraged to provide their opinions to the union negotiators before the claim is finalised.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less